Chronic kidney disease (CKD) is a major public health problem affecting an estimated 37 million American adults.1 Most people with CKD are unaware of their disease, even those with more advanced disease.2 Kidney failure requiring kidney replacement therapy is a relatively uncommon outcome, with a lifetime risk of approximately 3%-4%, although this is higher, approaching 8%-9%, among those of African ancestry.3-5 Moreover, one-third of US residents develop advanced CKD (defined as a glomerular filtration rate [GFR] < 45 mL/min, consistent with CKD stage 3b), with a significant impact on overall health, including increased risk of cardiovascular disease, cognitive impairment, anemia, and mineral and bone disorders.5,6 All of this contribute to high utilization of health care resources; high costs to governments, insurers, and individuals; and lost productivity with worse quality and duration of life.

In the past 2 decades, there have been significant advances in basic and clinical science related to CKD progression, including validation of surrogates for hard clinical endpoints that can be used in clinical trials of new CKD treatments, even early in the disease course.7,8 Recent approval of medicines to prevent the progression in later stages of CKD, as well as the use of surrogate endpoints in rare diseases with newer, disease-specific interventions, have established an environment that is primed for development and evaluation of treatments for common causes of CKD early in the disease course.9-11 Medications targeting kidney disease will only benefit a subset of individuals with or at risk of early-stage CKD, raising the question of who should receive the medications and when they should be received in the course of the disease. While risk prediction tools may improve the selection of those patients most likely to benefit from interventions that decrease the risk of CKD progression, there is still much to learn about why some patients progress and others do not and, in the absence of precise risk estimates,
patients may not be able to quantify their risk to weigh benefits of early treatment. In light of these factors, compounded with patients’ unique comorbid conditions, circumstances, and value preferences, it is not surprising that risk-versus-benefit conversations among clinicians, patients, and care partners are challenging.12-15 Given this, there is a clear imperative to assess peoples’ willingness and comfort with taking preventative medications in earlier-stage CKD. As no therapy is without side effects, it is particularly important to capture concerns regarding side effects that may have an impact on willingness to take a medication.

In December 2020, the National Kidney Foundation (NKF) and the US Food and Drug Administration (FDA) co-sponsored a scientific workshop to explore patients’, providers’, and payers’ perceptions of the value of treating early CKD. To inform this workshop, NKF surveyed their patient network on patient perspectives regarding their risk of kidney disease progression, as well as considerations important to patients in deciding whether or not to take new medications that could reduce their risk of progression.

METHODS

This observational survey aimed to assess the baseline knowledge of CKD, level of understanding of respondents’ current CKD status, and perceptions of the future risk of progression either to late-stage CKD or kidney failure. Additionally, survey questions were aimed at identifying individuals’ values and considerations in decision making about taking a medication that may or may not benefit them. This anonymized survey with minimal demographic data was designed to inform the conference proceedings and was not intended to develop generalizable knowledge; therefore, informed consent was not obtained.

Survey Development

The 26-question survey was developed with input from the conference planning committee, which included the researcher, clinician, patient, and regulatory members (Items S1 and S2). The planning committee first identified key topics that they thought would be critical to inform conference participants, including knowledge of CKD and the individual respondent’s current health, perception of their future kidney health risk and progression, and the value placed on minimizing side effects from medications to prevent progression. We used existing validated surveys to assess respondents’ knowledge about kidney disease and related signs or symptoms that a person might experience if they have advanced CKD or kidney failure.16 We reviewed a survey distributed to the heart-failure patient community before a similar conference.17 Drafts of the survey were then shared with patient reviewers from the NKF’s Kidney Advocacy Committee, and edits were made based on their feedback and insights.

To assess perspectives around the risks and benefits of taking a new medication, we developed scenarios that asked respondents to consider whether they would take a new medication that would reduce their risk of developing kidney failure over the next 20, 10, and 5 years, framed with the assumption that they had a 20% risk of developing kidney failure over those time periods. The time frame was selected based on a review of the literature, which describes progression rates in CKD populations that range from 2 to 5 mL/min per year.18,19 For example, for a patient starting at a GFR of 70 mL/min per 1.73 m², the patient would be at CKD stage 5 after 20 years. Responses to risk questions were ranked on a 5-point scale ranging from not likely to very likely. To assess perspectives on the tolerance of specific medications, we asked respondents to consider specific benefits and side effects, including how these side effects would impact their willingness to take the medication and how important certain factors are in deciding to take a new medication. We developed the list based both on common side effects for medications used in general (constipation) and for CKD (dizziness, increased urination), including known sodium/glucose co-transporter 2 side effects (increased urination, urinary tract infections).20 Many medications require monitoring and more frequent appointments and blood tests. Responses to these questions had 3 possible response choices: not important, important, or very important.

Dissemination

The survey was sent by the NKF in November 2020 via email to their database of 20,249 people not known to be currently receiving dialysis or living with a transplant. Links to the survey were also posted to the NKF’s Facebook page, which had 255,130 followers at the time of dissemination, and to 10 other kidney- and diabetes-related Facebook groups. Dissemination was purposefully broad to gain insight into how people think about risk at
various CKD stages. There was no incentive offered for completion.

RESULTS
Of 1,029 respondents, 49% were between 55 and 75 years old, 50% were women, 65% were White, and 52% had either a college or advanced degree; 55% identified as having nondialysis CKD, while 26% identified as a kidney transplant recipient. There was modest missingness on demographic questions. A total of 86% of respondents with CKD had been referred to a kidney specialist or nephrologist. There was a fairly even distribution among CKD stages 3a, 3b, and 4, while 8.7% of respondents indicated that they had CKD stages 1 or 2 (Table 1). A third of respondents were not sure whether they had protein in their urine (33%).

CKD Knowledge
Tables S1 and S2 show the results of respondents on knowledge questions. Respondents answered most knowledge questions correctly, with the lowest correct response rate of 74% elicited from the question, “What is the range that is usually considered to be normal for GFR?” (Table S1). Respondents also correctly identified the signs and symptoms of CKD (Table S2).

Risk-Benefit Assessments
The survey posed 3 major scenarios for respondents. Scenario 1 stated, “Your doctor says that there is a new medication which can reduce your chance of developing kidney failure. Please tell us your likelihood of taking this medication under the following circumstances.” Respondents were overall willing to take a medication that reduces their risk of kidney disease progression, and this willingness increased as the imminent threat of kidney failure increased (from 33% to 47% from 20 to 5 years, respectively; Fig 1). The percent of respondents who were not likely to take the medication was fairly stable, regardless of the imminence of kidney failure (12.1%, 9.7%, and 11.9% with 20, 10, and 5 years to kidney failure, respectively), with similar responses for men and women.

Scenario 2 stated, “If your doctor told you that you have a 20% chance of developing kidney failure over 5 years, how likely would you be to take a drug that has the following side effects or concerns?” Most factors listed were not a barrier to taking a medication for many patient respondents (Fig 2). Regular blood tests and more frequent doctor visits would not affect most respondents’ willingness to take a medication, with 75.8% and 73.1%, respectively, remaining likely or very likely to take medication. Other side effects, such as increased urination (61.5% likely or very likely), a chance of urinary tract infections (52.8% likely or very likely), occasional dizziness (45.1% likely or very likely), and mild to moderate constipation (43.4% likely or very likely), affected slightly larger percentages of people’s decision to take a medication.

Scenario 3 stated, “Imagine that you have started the medication. You notice that the side effects of the new drug are worse than you thought they would be. You talk to your doctor, and your doctor goes over the clinical evidence with you. You are convinced that the data show that the drug would significantly slow or prevent the progression of your kidney disease and that this will lead to a better quality of life down the road. How likely would you be to take this drug?” Respondents were overwhelmingly willing to continue taking the medication even if side effects occurred (93.8%), although the majority (58.7%) were only willing to continue if their doctor worked with them to try to reduce the side effects (Fig 3).

Considerations for Taking a New Medication
The most important factors for patients considering taking a new medication were the severity of the known side effects (60.6% very important), cost and whether the drug was covered by insurance (57.9% very important), and what their doctor recommends (55.4% very important; Table 2). The least concerning to patients was how often they needed to take medication (47.2% not important).

DISCUSSION
In a fairly well-informed population with access to nephrology care, as demonstrated by CKD knowledge questions and referrals to nephrologists, respondents were by and large willing to assume some side effects, particularly as the time frame of the potential benefit of medications to delay kidney failure shortened. Critically, clinician recommendations regarding kidney therapies and clinician willingness to work with patients to address any side effects were important in patients’ willingness to initiate and to persevere with a new medication. Risk-versus-benefit discussions appear key to patients and their families making well-informed decisions about taking a new medication that may or may not help the progression of their kidney disease.

When considering treatments for end of life or treatments for chronic conditions, patients typically are willing to accept some level of risk for degrees of potential benefit. For example, in 1 study of obesity management, most individuals considering bariatric surgery were willing to accept a 10% risk of death if it meant they would sustain greater than 20% weight loss; however, the majority were unwilling to accept the risk if sustained weight loss were projected to be 20% or less. Of note, a lower baseline quality of life was associated with a greater willingness to accept risk. Similarly, patients with hepatitis C virus infection were willing to accept an increased risk of side effects for a sufficient improvement in the likelihood of a treatment response. While benefits in these disease states are easily quantifiable in a relatively short time,
| Kidney disease causes                  | At Risk for CKD (n=45) | Have CKD (n=566) | Kidney Transplant (n=267) | Dialysis (n=51) | Other* or Blank (n=100) | Total (n=1,029) |
|----------------------------------------|------------------------|------------------|---------------------------|-----------------|------------------------|-----------------|
| Diabetic kidney disease                | 0.8% (8)               | 9.0% (93)        | 2.7% (28)                 | 1.1% (11)       | 0.0%                   | 13.6% (140)     |
| Polycystic kidney disease              | 0.2% (2)               | 6.3% (65)        | 5.3% (55)                 | 1.1% (11)       | 0.0%                   | 12.9% (133)     |
| Glomerulonephritis                     | 0.2% (2)               | 6.7% (69)        | 9.3% (96)                 | 1.3% (13)       | 0.0%                   | 17.5% (180)     |
| Other                                  | 1.9% (20)              | 25.1% (258)      | 8.5% (87)                 | 1.6% (16)       | 1.7% (18)              | 38.8% (399)     |
| Blank                                  | 1.5% (15)              | 10.9% (112)      | 1.6% (16)                 | 0.6% (6)        | 8.0% (82)              | 22.4% (231)     |
| Total                                  | 4.6% (47)              | 58.0% (597)      | 27.4% (282)               | 5.5% (57)       | 9.7% (100)             | 105.2%          |

- *eGFR, mL/min/1.73m²*

| Urine ACR                              |                        |                  |                           |                 |                       |                 |
|----------------------------------------|------------------------|------------------|---------------------------|-----------------|------------------------|-----------------|
| <30 mg/g                               | 1.1% (11)              | 12.7% (131)      | NA                        | NA              | 1.0% (8)               | 14.8% (152)     |
| 30-300 mg/g                            | 0.1% (1)               | 8.3% (85)        | NA                        | NA              | 0.4% (2)               | 8.8% (90)       |
| >300 mg/g                              | 0.2% (2)               | 3.1% (32)        | NA                        | NA              | 0.0%                   | 3.3% (34)       |
| Unsure                                 | 2.8% (29)              | 28.2% (290)      | NA                        | NA              | 2.0% (17)              | 33.0% (339)     |
| Blank                                  | 0.2% (2)               | 2.7% (28)        | 25.5% (262)               | 4.8% (49)       | 7.1% (73)              | 40.2% (414)     |
| Total                                  | 4.4% (45)              | 55.0% (567)      | 25.5% (269)               | 4.8% (54)       | 10.5% (104)            | 100.1%          |

- *Risk factors*

| Diabetes                               | 1.3% (13)              | 12.2% (126)      | NA                        | NA              | 0.5% (3)               | 14.0% (144)     |
| Heart condition                        | 0.7% (7)               | 9.4% (97)        | NA                        | NA              | 0.3% (1)               | 10.4% (107)     |
| Overweight or obese                    | 1.5% (15)              | 19.0% (195)      | NA                        | NA              | 0.8% (7)               | 21.2% (218)     |
| High blood pressure                    | 2.7% (28)              | 37.3% (384)      | NA                        | NA              | 1.4% (14)              | 41.4% (426)     |
| Sickle cell disease                    | 0.1% (1)               | 0.2% (2)         | NA                        | NA              | 0.0%                   | 0.3% (3)        |
| Kidney cancer                          | 0.4% (4)               | 1.7% (18)        | NA                        | NA              | 0.4% (4)               | 2.5% (26)       |
| HIV or AIDS                            | 0.0%                   | 0.0%             | NA                        | NA              | 0.0%                   | 0.0%            |
| Other                                  | 0.6% (6)               | 8.6% (88)        | NA                        | NA              | 1.1% (11)              | 10.2% (105)     |
| Blank                                  | 0.2% (2)               | 5.9% (61)        | 25.5% (262)               | 4.8% (49)       | 7.2% (74)              | 43.5% (448)     |
| Total                                  | 7.4% (76)              | 94.4% (971)      | 26.3% (271)               | 5.1% (52)       | 10.4% (107)            | 143.5%          |

- *Age, y*

| 18-44                                  | 0.3% (3)               | 3.7% (38)        | 2.0% (21)                 | 0.5% (5)        | 0.4% (4)               | 6.9% (71)       |
| 45-54                                  | 0.3% (3)               | 4.6% (47)        | 5.2% (53)                 | 0.5% (5)        | 0.1% (1)               | 10.6% (109)     |
| 55-64                                  | 1.1% (11)              | 9.4% (97)        | 7.7% (79)                 | 1.1% (11)       | 0.6% (6)               | 19.8% (204)     |
| 65-75                                  | 1.2% (12)              | 19.7% (203)      | 6.4% (66)                 | 1.3% (13)       | 0.6% (6)               | 29.2% (300)     |
| 76-85                                  | 0.5% (5)               | 7.9% (81)        | 0.6% (6)                  | 0.7% (7)        | 0.5% (5)               | 10.1% (104)     |
| 85+                                    | 0.1% (1)               | 1.6% (16)        | 0.0%                      | 0.0%            | 0.1% (1)               | 1.7% (18)       |
| Unanswered                             | 1.0% (10)              | 8.2% (80)        | 4.1% (42)                 | 1.0% (10)       | 7.5% (77)              | 21.3% (223)     |
| Total                                  | 4.4% (45)              | 55.0% (566)      | 25.9% (267)               | 5.0% (51)       | 9.7% (100)             | 100.0%          |

- *Gender*

| Male                                   | 1.1% (11)              | 14.9% (153)      | 10.1% (104)               | 1.7% (17)       | 0.9% (9)               | 28.6% (294)     |
| Female                                 | 2.3% (24)              | 31.6% (325)      | 11.8% (121)               | 2.3% (24)       | 1.5% (15)              | 49.5% (509)     |
| Unanswered                             | 1.0% (10)              | 8.6% (88)        | 4.1% (42)                 | 1.0% (10)       | 7.4% (76)              | 22.0% (226)     |
| Total                                  | 4.4% (45)              | 55.0% (566)      | 25.9% (267)               | 5.0% (51)       | 9.7% (100)             | 100.0%          |

- *Race*

| White                                  | 2.2% (23)              | 40.8% (420)      | 16.9% (174)               | 3.3% (34)       | 2.0% (21)              | 65.3% (672)     |
| Black or African American              | 0.6% (6)               | 2.9% (30)        | 3.3% (34)                 | 0.5% (5)        | 0.1% (1)               | 7.4% (76)       |

(Continued)
kidney disease poses unique challenges in risk-versus-benefit discussions, with not only relatively low percentages of people with CKD progressing to kidney failure but also a high burden of associated comorbid conditions that may affect a patient's lifestyle, overall health, and mortality. While this survey was developed in preparation for the workshop, a clear consensus emerged from the workshop that there is value in preventing the prevention of CKD.
development or treating the progression of early CKD in people who are at high risk for progression (workshop report in preparation). It is important to gain further insight into the level of risk or side effects patients with early-stage CKD are willing to assume to decrease their chance of progressing to late-stage CKD or kidney failure.

One theme from respondents was that the opinions of their physicians and working with their physicians to address side effects were important for initiating and continuing potentially risk-lowering treatments. Despite the potential reticence of clinicians to have complex risk-progression discussions with patients, the reality is that clinicians’ professional insights and opinions carry significant impacts on patients’ willingness to consider new medications or treatments.15,26 This is true even among the well-educated population who responded to the survey reported here. Ideally, these conversations begin early and continue over time, in an iterative process combining education and preference discussions. These efforts are key to engaging patients as partners and can have a significant impact on patient activation and overall health.27

Newer and emerging treatments to prevent kidney disease progression offer new opportunities and challenges for researchers, regulators, and clinicians. Our results showed that people with CKD are willing to accept some risk and some burden of side effects. This can inform the recommendations that emerge from the workshop about treatments of early CKD. While our survey used a 20% risk over a 5- to 20-year time span to frame this scenario, some patients may internalize a risk differently depending on how the risk is presented; for example, a patient may view a 20% risk as minimal while also viewing a 1 in 5 risk as significant, despite their mathematical equivalence. Further qualitative research is needed to fully understand patients’ perspectives and preferences in how this critical information is presented and interpreted and to identify universal best practices for translating statistical risks into narrative frameworks.

CKD is often an asymptomatic disease until late in the disease course. This presents challenges regarding how to assess patients’ perceptions and priorities in earlier stages of CKD. The NKF is deeply engaged in this challenge with public health campaigns (“Are You the 33%”) and a recently launched CKD Patient Registry (the NKF Patient Network).28 For the purpose of informing the conference participants, we purposefully elected to send the survey to the broad NKF audience to gain insight into how people think about risk at various CKD stages. Further, people with early-stage CKD may not appreciate the “burden” of CKD yet. Thus, while individuals with late-stage CKD, including those receiving dialysis or living with a kidney transplant, have an inherent bias, they offer valuable

---

**Figure 1.** Responses to scenario 1, regarding the likelihood of taking a new medication to prevent kidney failure. Scenario 1 stated, “Your doctor says that there is a new medication which can reduce your chance of developing kidney failure. Please tell us your likelihood of taking this medication under the following circumstances.”

**Figure 2.** Responses to scenario 2, regarding symptoms that would impact medication willingness. Scenario 2 stated, “If your doctor told you that you have a 20% chance of developing kidney failure over 5 years, how likely would you be to take a drug that has the following side effects or concerns?” More frequent appointments and blood tests refer to approximately every 3 months. Abbreviation: UTI, urinary tract infection.

**Figure 3.** Responses to scenario 3, regarding willingness to continue use if side effects occurred. Scenario 3 stated, “Imagine that you have started the medication. You notice that the side effects of the new drug are worse than you thought they would be. You talk to your doctor, and your doctor goes over the clinical evidence with you. You are convinced that the drug will significantly slow or prevent the progression of your kidney disease and that this will lead to a better quality of life down the road. How likely would you be to take this drug?”
Table 2. Responses to the Question “How Important Are Each of the Following to You When Deciding to Select a New Drug?”

|                      | Not Important | Important | Very Important |
|----------------------|---------------|-----------|----------------|
| The drug is a pill that can be taken by mouth | 28.2% (230) | 36.7% (303) | 35.1% (287) |
| How often you take the drug | 47.2% (376) | 38.9% (314) | 13.9% (114) |
| Number of side effects known for the drug | 6.5% (52) | 51.5% (423) | 42% (342) |
| Severity of side effects known for drug | 3.3% (26) | 36.1% (288) | 60.6% (489) |
| Cost and/or if covered by insurance | 9.8% (79) | 32.3% (267) | 57.9% (474) |
| What your physician recommends | 3.2% (25) | 41.4% (330) | 55.4% (443) |

insight into questions posed by the survey. Indeed, patients with more advanced CKD often noted a shift in their own personal journey when they became more active and involved in their care. This journey informed the workshop participants and guided recommendations about the importance of educating patients with early CKD before engaging with them in the discussion about treatment options.

Although this study included broad ranges of ages, stages of CKD, and likely causes of kidney disease, there were a number of limitations. First, although the survey was emailed to more than 20,000 individuals identifying with CKD in the NKF database, only approximately 5% of this number completed a survey. Respondents may also have seen the survey on alternative media. Importantly, the population who receive NKF communications or follow NKF on social media likely differ from the broader CKD population, resulting in a largely White, well-educated population of respondents who have been referred to a nephrologist. This has implications for generalizability, as CKD disproportionately affects individuals with a lower socioeconomic status and less health literacy. Second, many respondents had already progressed to advanced kidney disease and, while they may be able to reflect meaningfully on their experience in hindsight, those with newly recognized, earlier-stage disease may have a differing, more nuanced perspective. Additionally, those with genetic diseases like polycystic kidney disease may be more inclined to accept risks even with a higher GFR, as they have seen family members live and die from kidney disease. Third, the 5-, 10- and 20-year time horizons and 20% likelihood posed in scenarios for developing kidney failure are somewhat arbitrary; however, they are consistent with potential patterns of kidney disease progression in people with CKD. Critically, there remains a need to collect additional data in individuals with earlier stages of disease to inform our understanding of the potential acceptability of tradeoffs between treatment benefits and risks in patients with early stages of disease.

While insights gleaned from this work may have some universal applications, additional research into the priorities of a larger population of individuals with earlier-stage kidney disease, as well as those from diverse cultural and socioeconomic backgrounds and those with less education, access to nephrology care, and trust in health care providers, is warranted. Insofar as the respondents are more likely to have access to ongoing health care than are populations not reached by the survey, they may also perceive that delaying disease progression is less critical, as later monitoring and care might address future “problems.” Additionally, as lifestyle, behavior, and treatment adherence are increasingly seen as meaningful variables in risk management, further research to explore patient activation and willingness to take a risk-reducing medication may enrich future discussions.

In sum, among a population of well-informed individuals with CKD, there was a willingness to assume risk in seeking treatment to slow the progression of kidney disease, reinforcing the broader population’s need for more frequent and earlier education about kidney disease risk progression. For this population, who are likely to have positive engagement with the health care system, physicians’ recommendations regarding therapies and input in managing potential side effects are meaningful, and developing best practices for engaging patients, transcending biases and cultural differences, and presenting a risk to patients will aid in increased clinician comfort with these difficult, yet necessary, conversations.

SUPPLEMENTARY MATERIAL

Supplementary File (PDF)

Item S1: Workshop Planning Committee.

Item S2: CKD patient survey.

Table S1: Survey respondent answers to CKD knowledge questions.

Table S2: Knowledge table of signs and symptoms of advanced CKD.

ARTICLE INFORMATION

Authors’ Full Names and Academic Degrees: Kelli Collins Damron, MSW, Robert Friedman, MSW, Lesley A. Inker, MD, MS, Aliza Thompson, MD, MS, Morgan E. Grams, MD, MHS, PhD, Hrefna Guðmundsdóttir, MD, PhD, Kerry Willis, PhD, Tom Manley, RN, Hiddo L. Heerspink, PharmD, PhD, Daniel E. Weiner, MD, MS

Authors’ Affiliations: National Kidney Foundation (KCD, KW, TM), New York, NY; Brooklyn, NY (RF); Division of Nephrology (LAI, DEW), Tufts Medical Center, Boston, MA; US Food and Drug Administration (AT), Silver Spring, MD; Department of Epidemiology (MEG), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; Icelandic Medicines Agency (HG), Lyfjastofnun Islands, Iceland; Clinical Pharmacy and Pharmacology and Nephrology (HLH), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Financial Disclosure: Mr Friedman is an AstraZeneca stockholder. Dr Inker has received funding to her institute for research and has served as a consultant to AbbVie, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Novartis, Travere, and Vertex. Workshop sponsors had no role in the development of the workshop agenda or objectives nor in the study design; collection, analysis, and interpretation of data; writing the report; or the decision to submit the report for publication.

Support: No support was provided for the development of the survey. The following companies provided a grant to the National Kidney Foundation to support planning and conduct of the 2020 NKF-FDA Scientific Workshop on Clinical Trial Considerations for Developing Treatments for Early Stages of Chronic Kidney Disease: AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, Travere Therapeutics, and Vertex. Workshop sponsors had no role in the development of the workshop agenda or objectives nor in the study design; collection, analysis, and interpretation of data; writing the report; or the decision to submit the report for publication.

References:

1. Tuot DS, Wong KK, Velasquez A, et al. CKD awareness in the general population: performance of CKD-specific questions. Kidney Med. 2019;1(2):43-50.
2. Chu CD, McCulloch CE, Banerjee T, et al. CKD awareness among US adults by future risk of kidney failure. Am J Kidney Dis. 2020;76(2):174-183.
3. Albertus P, Morgenstern H, Robinson B, Saran R. Risk of ESRD in the United States. Am J Kidney Dis. 2016;68(6):862-872.
4. Grams ME, Chow EK, Segev DL, Coresh J. Lifetime incidence of CKD stages 3-5 in the United States. Am J Kidney Dis. 2013;62(2):245-252.
5. Turin TC, Tonelli M, Manns BJ, et al. Lifetime risk of ESRD. J Am Soc Nephrol. 2012;23(9):1569-1578.
6. Sarnak MJ, Amann K, Bangalore S, et al. Chronic kidney disease and coronary artery disease: JACC state-of-the-art review. J Am Coll Cardiol. 2019;74(14):1823-1838.
7. Levey AS, Inker LA, Matsushita K, et al. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis. 2014;64(6):821-835.
8. Levey AS, Gansevoort RT, Coresh J, et al. Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency. Am J Kidney Dis. 2020;75(1):84-104.
9. Yu Z, Rebholz CM, Wong E, et al. Association between hypertension and kidney function decline: the Atherosclerosis Risk in Communities (ARIC) study. Am J Kidney Dis. 2019;74(3):310-319.
10. Tuttle KR, Brossius FC III, Cavender MA, et al. SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation. Am J Kidney Dis. 2021;77(1):94-109.
11. Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219-2229.
12. Karlin J, Chesla CA, Grubbs V. Dialysis or death: a qualitative study of older patients’ and their families’ understanding of kidney failure treatment options in a US public hospital setting. Kidney Med. 2019;1(3):124-130.
13. Davison SN. Facilitating advance care planning for persons with end-stage renal disease: the patient perspective. Clin J Am Soc Nephrol. 2006;1(5):1023-1028.
14. Raj R, Thrivengadam S, Ahuja KDK, Frandsen M, Jose M. Discussions during shared decision-making in older adults with advanced renal disease: a scoping review. BMJ Open. 2019;9(11):e031427.
15. Schell JO, Patel UD, Steinhauser KE, Ammaren N, Tulska YJ. Discussions of the kidney disease trajectory by elderly patients and nephrologists: a qualitative study. Am J Kidney Dis. 2012;59(4):495-503.
16. Wright JA, Wallston KA, Elasy TA, Ikizler TA, Cavanaugh KL. Development and results of a kidney disease knowledge survey given to patients with CKD. Am J Kidney Dis. 2011;57(3):387-395.
17. Fiuzat M, Lowy N, Stockbridge N, et al. Endpoints in heart failure drug development: history and future. JACC Heart Fail. 2020;8(6):429-440.
18. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;83:1-150.
19. Inker LA, Heerspink HJL, Tighiouart H, et al. GFR slope as a surrogate end point for kidney disease progression in clinical trials: a meta-analysis of treatment effects of randomized controlled trials. J Am Soc Nephrol. 2019;30(9):1735-1745.
20. US Food and Drug Administration. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections: FDA Drug Safety Communication. Accessed January 18, 2022. https://www.fda.gov/drugs/drug-safety-and-availability/
21. Wee CC, Hamel MB, Apovian CM, et al. Expectations for weight loss and willingness to accept risk among patients seeking weight loss surgery. *JAMA Surg.* 2013;148(3):264-271.

22. Kauf TL, Mohamed AF, Hauber AB, Fetzer D, Ahmad A. Patients’ willingness to accept the risks and benefits of new treatments for chronic hepatitis C virus infection. *Patient.* 2012;5(4):265-278.

23. Couchoud C, Hemmelgarn B, Kotanko P, Germain MJ, Moranne O, Davison SN. Supportive care: time to change our prognostic tools and their use in CKD. *Clin J Am Soc Nephrol.* 2016;11(10):1892-1901.

24. González AM, Gutman T, Lopez-Vargas P, et al. Patient and caregiver priorities for outcomes in CKD: a multinational nominal group technique study. *Am J Kidney Dis.* 2020;76(5):679-689.

25. Hanson CS, Gutman T, Craig JC, et al. Identifying important outcomes for young people with CKD and their caregivers: a nominal group technique study. *Am J Kidney Dis.* 2019;74(1):82-94.

26. Ladin K, Neckermann I, D’Arcangelo N, et al. Advance care planning in older adults with CKD: patient, care partner, and clinician perspectives. *J Am Soc Nephrol.* 2021;32(6):1527-1535.

27. Oskoui T, Pandya R, Weiner DE, Wong JB, Koch-Weser S, Ladin K. Advance care planning among older adults with advanced non-dialysis-dependent CKD and their care partners: perceptions versus reality? *Kidney Med.* 2020;2(2):116-124.

28. National Kidney Foundation. NKF Patient Network. Accessed January 18, 2022. https://www.kidney.org/nkfpatientnetwork